A small molecule outclasses larger ones in combating drug-resistant bacteria that cause skin infections

April 6, 2016, Agency for Science, Technology and Research (A*STAR), Singapore
A small molecule outclasses larger ones in combating drug-resistant bacteria that cause skin infections
Electron micrograph of Methicillin-resistant Staphylococcus aureus (MRSA), which is becoming increasingly difficult to treat due to increased drug resistance. A*STAR researchers have designed a small molecule containing four amino acids that is effective in killing such bacteria quickly and efficiently. Credit: A*STAR Experimental Therapeutics Centre and IMB-IMCB Joint Electron Microscopy Suite

A promising drug candidate to address the growing problem of antibiotic-resistant skin infections has been discovered by A*STAR researchers.

Bacteria known as Methicillin-resistant Staphylococcus aureus (MRSA) (see image) is the primary cause of human skin infections and is now endemic in many hospitals worldwide. Such infections are becoming harder to treat because an increasing number of MRSA strains are becoming resistant to standard antibiotics. Besides causing painful and unsightly skin conditions, MRSA infections can lead to more severe complications, such as surgical wound and catheter-related infections, blood poisoning, bone infections and pneumonia.

The arsenal available to fight the disease is rapidly shrinking for two reasons. Firstly, standard antibiotics have become less effective as the bacteria develop resistance to them and secondly, pharmaceutical companies are reluctant to invest in the costly search for new antibiotics due to the perceived low profitability in this research area.

Brian Chia of the A*STAR Experimental Therapeutics Centre and his co-workers have now designed and synthesized a new potential weapon in the battle against MRSA ― a very short antimicrobial peptide.

Peptides are organic polymers made up of amino acid building blocks linked in a chain by peptide bonds. By designing peptides with specific amino acid sequences, researchers can tune peptides to target and disrupt bacterial membranes. Because quickly disrupt bacterial membranes, bacteria have little time to mutate and develop drug resistance. 

A major hurdle in developing antimicrobial peptides as drugs is that their relatively large molecular sizes make them expensive to manufacture on a large scale. The team solved this problem by designing an ultra-short peptide that consists of only four amino acids. In contrast, the shortest antimicrobial peptide currently in clinical trials, Omiganan, consists of 12 amino acids. 

The researchers compared the MRSA-killing ability of their antimicrobial peptide with other antimicrobial peptide clinical candidates as well as anti MRSA antibiotics currently prescribed by doctors. 

The results were highly encouraging. "Our antimicrobial peptide far exceeded our initial expectations," says Chia. "Our four-residue peptide has an anti MRSA potency on par with that of the current shortest antimicrobial peptide ― but it is three times shorter. Plus, because it consists of only two types of , drug manufacturing cost and time should be drastically reduced." 

The team is currently working on formulating the antimicrobial peptide into a topical gel for pre-clinical studies.

Explore further: HIV-derived antibacterial shows promise against drug-resistant bacteria

More information: Qiu Ying Lau et al. Discovery of an ultra-short linear antibacterial tetrapeptide with anti-MRSA activity from a structure–activity relationship study, European Journal of Medicinal Chemistry (2015). DOI: 10.1016/j.ejmech.2015.10.015

Related Stories

HIV-derived antibacterial shows promise against drug-resistant bacteria

June 19, 2013
A team of researchers at the University of Pittsburgh has developed antibacterial compounds, derived from the outer coating of HIV, that could be potential treatments for drug-resistant bacterial infections and appear to ...

Antimicrobial stewardship improves outcomes for MRSA

December 30, 2015
(HealthDay)—For patients receiving antimicrobial injections targeting methicillin-resistant Staphylococcus aureus (MRSA), implementation of an antimicrobial stewardship program that includes daily review of prescriptions ...


July 22, 2013
Antimicrobial peptides are natural antibiotics found in all multicellular organisms. These molecules are viewed as potential drug candidates in the post-antibiotic era because widespread microbial resistance against them ...

Recommended for you

Antibody 'cocktail' can prevent Zika infection but is not effective for treatment of fetuses

April 26, 2018
A "cocktail" of monoclonal antibodies that can prevent Zika virus (ZIKV) infection in primates was not effective for treatment of fetuses, according to a new collaborative study led by a University of Miami Miller School ...

E. coli—are we measuring the wrong thing?

April 25, 2018
A sepsis awareness and management programme has demonstrated overall success in terms of improved sepsis detection, but has led to an increase in the number of E. coli blood stream infection cases presented, calling into ...

Malaria study reveals gene variants linked to risk of disease

April 25, 2018
Many people of African heritage are protected against malaria by inheriting a particular version of a gene, a large-scale study has shown.

Commonly prescribed heartburn drug linked to pneumonia in older adults

April 24, 2018
Researchers at the University of Exeter have found a statistical link between pneumonia in older people and a group of medicines commonly used to neutralise stomach acid in people with heartburn or stomach ulcers. Although ...

Kids with rare rapid-aging disease get hope from study drug

April 24, 2018
Children with a rare, incurable disease that causes rapid aging and early death may live longer if treated with an experimental drug first developed for cancer patients, a study suggests.

Early treatment for leg ulcers gets patients back on their feet

April 24, 2018
Treating leg ulcers within two weeks by closing faulty veins improves healing by 12 per cent compared to standard treatment, according to new findings.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.